These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 26860246)

  • 1. Commentary on Enns et al. (2016): Supervised injection facilities as a cost-effective intervention.
    Fairbairn N; Wood E
    Addiction; 2016 Mar; 111(3):490-1. PubMed ID: 26860246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential cost-effectiveness of supervised injection facilities in Toronto and Ottawa, Canada.
    Enns EA; Zaric GS; Strike CJ; Jairam JA; Kolla G; Bayoumi AM
    Addiction; 2016 Mar; 111(3):475-89. PubMed ID: 26616368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Ottawa, Canada.
    Jozaghi E; Reid AA; Andresen MA; Juneau A
    Subst Abuse Treat Prev Policy; 2014 Aug; 9():31. PubMed ID: 25091704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of harm reduction.
    Wilson DP; Donald B; Shattock AJ; Wilson D; Fraser-Hurt N
    Int J Drug Policy; 2015 Feb; 26 Suppl 1():S5-11. PubMed ID: 25727260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The projected costs and benefits of a supervised injection facility in Seattle, WA, USA.
    Hood JE; Behrends CN; Irwin A; Schackman BR; Chan D; Hartfield K; Hess J; Banta-Green C; Whiteside L; Finegood B; Duchin J
    Int J Drug Policy; 2019 May; 67():9-18. PubMed ID: 30802842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of harm reduction for injection drug use: A clinical and public health ethics analysis.
    Vearrier L
    Dis Mon; 2019 May; 65(5):119-141. PubMed ID: 30600096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of combination approach on harm reduction programs: the Taiwan experience.
    Lin T; Chen CH; Chou P
    Harm Reduct J; 2016 Jul; 13(1):23. PubMed ID: 27377896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circumstances of first injection among illicit drug users accessing a medically supervised safer injection facility.
    Kerr T; Tyndall MW; Zhang R; Lai C; Montaner JS; Wood E
    Am J Public Health; 2007 Jul; 97(7):1228-30. PubMed ID: 17538061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost-benefit and cost-effectiveness analysis of Vancouver's supervised injection facility.
    Andresen MA; Boyd N
    Int J Drug Policy; 2010 Jan; 21(1):70-6. PubMed ID: 19423324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measuring effectiveness of needle and syringe exchange programs for prevention of HIV among injecting drug users: Response to Amundsen.
    Maher L; Iversen J; Kaldor J
    Addiction; 2006 Dec; 101(12):1834-6. PubMed ID: 17156184
    [No Abstract]   [Full Text] [Related]  

  • 11. Mitigating the heroin crisis in Baltimore, MD, USA: a cost-benefit analysis of a hypothetical supervised injection facility.
    Irwin A; Jozaghi E; Weir BW; Allen ST; Lindsay A; Sherman SG
    Harm Reduct J; 2017 May; 14(1):29. PubMed ID: 28532488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is Vancouver Canada's supervised injection facility cost-saving?
    Pinkerton SD
    Addiction; 2010 Aug; 105(8):1429-36. PubMed ID: 20653622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attendance at supervised injecting facilities and use of detoxification services.
    Wood E; Tyndall MW; Zhang R; Stoltz JA; Lai C; Montaner JS; Kerr T
    N Engl J Med; 2006 Jun; 354(23):2512-4. PubMed ID: 16760459
    [No Abstract]   [Full Text] [Related]  

  • 14. Studies confirm effectiveness of harm reduction for people who inject drugs.
    Arkin E
    HIV AIDS Policy Law Rev; 2011 Oct; 15(3):29. PubMed ID: 22165261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Montreal, Canada.
    Jozaghi E; Reid AA; Andresen MA
    Subst Abuse Treat Prev Policy; 2013 Jul; 8():25. PubMed ID: 23837814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Supervised Injection Facilities as Harm Reduction: A Systematic Review.
    Levengood TW; Yoon GH; Davoust MJ; Ogden SN; Marshall BDL; Cahill SR; Bazzi AR
    Am J Prev Med; 2021 Nov; 61(5):738-749. PubMed ID: 34218964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Examining the potential role of a supervised injection facility in Saskatoon, Saskatchewan, to avert HIV among people who inject drugs.
    Jozaghi E; Jackson A
    Int J Health Policy Manag; 2015 Mar; 4(6):373-9. PubMed ID: 26029896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ODYSSEAS: supervised use of drugs versus bureaucracy in Greece.
    Malliori M; Galinaki S; Papakonstantinou AK
    Lancet Psychiatry; 2015 Feb; 2(2):e3. PubMed ID: 26359756
    [No Abstract]   [Full Text] [Related]  

  • 19. Supervised injection facilities in Canada: past, present, and future.
    Kerr T; Mitra S; Kennedy MC; McNeil R
    Harm Reduct J; 2017 May; 14(1):28. PubMed ID: 28521829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of harm reduction in preventing hepatitis C among injection drug users.
    Pollack HA
    Med Decis Making; 2001; 21(5):357-67. PubMed ID: 11575485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.